Heart patients may get safer blood thinner options after stents
NCT ID NCT05681702
First seen Nov 06, 2025
Summary
This study tests two ways to lower bleeding risk in people who have had a heart stent and take blood thinners. One plan switches to a milder drug while keeping aspirin; the other stops aspirin and keeps the stronger drug. Researchers will measure how well each plan prevents blood clots in 90 participants. The goal is to find which approach is safer without raising heart attack risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Florida
RECRUITINGJacksonville, Florida, 32209, United States
Contact Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
aspirin, clopidogrel, prasugrel, ticagrelor
What this could lead to
If successful, this could help doctors choose the best blood-thinner plan to reduce bleeding risk after heart stent procedures.
What could go wrong
This is a small, early-phase study (90 people) measuring lab effects, not actual bleeding events. Results may not translate to real-world benefits or apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.